Hans Wildiers

机构：KU Leuven

发表论文 17 篇 · 总被引 721 次 · h-index 5

代表论文

• Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (2024 · New England Journal of Medicine · 被引 440)
• Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (2018 · JAMA Oncology · 被引 149)
• HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology (2019 · Journal of Geriatric Oncology · 被引 48)
• Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer (2010 · Breast Cancer Research and Treatment · 被引 48)
• Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors (2013 · Supportive Care in Cancer · 被引 26)
• European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study (2025 · Frontiers in Oncology · 被引 3)